Aquestive Therapeutics (AQST) Accounts Payables (2017 - 2026)
Aquestive Therapeutics (AQST) posted quarterly Accounts Payables of $11.9 million for Q1 2026, down 3.18% year-over-year from $12.3 million in Q1 2025, and down 60.19% quarter-over-quarter from $29.9 million in Q4 2025.
Aquestive Therapeutics (AQST) Accounts Payables (2017 - 2026) Analysis & Trends
Aquestive Therapeutics' Accounts Payables history runs 10 years deep, the most recent figure standing at $11.9 million for Q1 2026.
- In Q1 2026, Accounts Payables fell 3.18% year-over-year to $11.9 million; the TTM figure through Mar 2026 stood at $11.9 million (down 3.18% YoY), while the FY2025 annual figure was $29.9 million, up 190.29% from the prior year.
- Accounts Payables for Q1 2026 stood at $11.9 million, down from $29.9 million in the prior quarter.
- The five-year high for Accounts Payables was $29.9 million in Q4 2025, with the low at $5.7 million in Q2 2024.
- The 5-year median for Accounts Payables is $10.5 million (2024), against an average of $11.3 million.
- The sharpest annual moves came in 2024 and 2025: Accounts Payables tumbled 46.71% in 2024, then surged 190.29% in 2025.
- Aquestive Therapeutics' Accounts Payables stood at $9.9 million in 2022, then retreated by 10.26% to $8.9 million in 2023, then advanced by 15.25% to $10.3 million in 2024, then soared by 190.29% to $29.9 million in 2025, then slumped by 60.19% to $11.9 million in 2026.
- Business Quant data shows AQST's Accounts Payables at $11.9 million in Q1 2026, $29.9 million in Q4 2025, and $10.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | -5.09 Bn |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 2.72 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 452.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 2.80 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 497.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 1.73 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 808.30 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 427.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 356.00 Mn |
| 10 | Aquestive Therapeutics | 554.35 Mn | 554.35 Mn | 9.80 Mn | 8.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.97 Mn |
| Mar 31, 2026 | 11.89 Mn |
| Dec 31, 2025 | 29.86 Mn |
| Sep 30, 2025 | 10.87 Mn |
| Jun 30, 2025 | 11.95 Mn |
| Mar 31, 2025 | 12.28 Mn |
| Dec 31, 2024 | 10.29 Mn |
| Sep 30, 2024 | 7.57 Mn |
| Jun 30, 2024 | 5.70 Mn |
| Mar 31, 2024 | 10.52 Mn |
| Dec 31, 2023 | 8.93 Mn |
| Sep 30, 2023 | 9.99 Mn |
| Jun 30, 2023 | 10.69 Mn |
| Mar 31, 2023 | 12.44 Mn |
| Dec 31, 2022 | 9.95 Mn |
| Sep 30, 2022 | 11.07 Mn |
| Jun 30, 2022 | 8.89 Mn |
| Mar 31, 2022 | 8.50 Mn |
| Dec 31, 2021 | 8.31 Mn |
| Sep 30, 2021 | 6.22 Mn |